Indaptus Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc. (ticker: INDP) is a U.S.-listed biotechnology company trading on Nasdaq, therefore on the NYSE/NASDAQ ecosystem, with headquarters in New York, United States. The company is a clinical-stage biotech focused on developing novel therapies for cancer and viral infections. Its corporate history is relatively recent and reflects a 2021 restructuring and rebranding around the Decoy Biosystems asset, after which the business began operating as Indaptus Therapeutics. As is typical for an early-stage biotech, the company remains heavily R&D-driven, has limited operating history, and depends on external capital to advance development. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1857044/000149315221018935/form8-k.htm?utm_source=openai)) Indaptus’ core business is built around a proprietary systemically administered immunotherapy platform, centered on its Decoy product candidates, with Decoy20 currently the lead program. The scientific concept is to deliver an intravenous therapy designed to activate anti-tumor and anti-viral immune responses. In its materials, the company highlights preclinical work showing tumor eradication when Decoy candidates were combined with PD-1 checkpoint inhibitors, low-dose chemotherapy, non-steroidal anti-inflammatory drugs, or approved targeted antibodies. Indaptus also emphasizes a safety-oriented design, noting that nonclinical toxicology studies did not show sustained induction of key cytokine release syndrome biomarkers, which may help differentiate the platform in a crowded immuno-oncology landscape. ([globenewswire.com](https://www.globenewswire.com/news-release/2025/06/02/3091794/0/en/indaptus-therapeutics-doses-first-patient-in-phase-1b-2-combination-study-of-decoy20-with-pd-1-checkpoint-inhibitor-tislelizumab.html)) From a competitive standpoint, Indaptus operates in one of the most contested areas of biotech: immuno-oncology and antiviral immunotherapy. The company does not compete on scale, manufacturing breadth, or commercial infrastructure; instead, its value proposition rests on scientific differentiation, patent protection, and the potential to create combination regimens that improve efficacy without unacceptable toxicity. A notable strategic step was the company’s securing of new patents in China, Japan, and Israel covering Decoy bacterial compositions for the prevention or treatment of hepatitis B virus and HIV. For investors, that supports an IP-led thesis: if the platform translates into clinical benefit, the company could attract partnership interest or broader development opportunities. ([globenewswire.com](https://www.globenewswire.com/news-release/2025/03/13/3042088/0/en/indaptus-therapeutics-reports-fourth-quarter-and-year-end-2024-financial-results-and-provides-corporate-update.html)) Geographically, Indaptus is primarily based in the United States, with principal executive offices at 3 Columbus Circle in New York City; its SEC filings also reference prior office space in San Diego, California. Recent milestones underline the company’s clinical momentum. In March 2025, Indaptus said it had entered a clinical supply agreement with BeiGene to evaluate Decoy20 in combination with tislelizumab, and in June 2025 it announced dosing of the first patient in the Phase 1b/2 expansion study. Most recently, the company’s first-quarter 2026 update stressed both the promise and the risk profile of the business: development is advancing, but financing needs, going-concern risk, and the uncertain path from preclinical and early clinical data to approved products remain central investment considerations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001857044/000149315226010585/form10-k.htm))